Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
NCT06931405Phase 2Active, not recruiting
- Sponsor
- Blueprint Medicines
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of BLU-808 in chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU), sponsored by Blueprint Medicines. Started May 2025; status: active, not recruiting.
02
Drugs
BLU-808
03
Conditions
chronic inducible urticaria (CIndU)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06931405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931405.